CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6809-6814

  Chang, Zhengqi ^a   Song, Ruoxian ^a   Xu, Songfeng ^a   Xu, Ming ^a   Yu, Xiuchun ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

CD 152; Osteosarcoma; Polymorphism

Indexed keywords

ALLELE; ARTICLE; CANCER RISK; CD 152 GENE; CHINA; CHINESE; DATA BASE; GENE; GENETIC ASSOCIATION; GENETIC RISK; HOMOZYGOTE; HUMAN; MEDLINE; OSTEOSARCOMA; PRIORITY JOURNAL; PUBLISHING; RECESSIVE INHERITANCE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CTLA-4 ANTIGEN; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; OSTEOSARCOMA; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84905036016     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1891-3     Document Type: Article

References (32)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-8. (Pubitemid 35363648)
2. Kämmerer PW, Toyoshima T, Schöder F, Kämmerer P, Kuhr K, Brieger J, et al. Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma. Oral Oncol. 2010;46(7):543-8.
3. Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68(8):698-704. (Pubitemid 47126657)
4. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48. (Pubitemid 40563179)
5. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. 2006;212:131-48. (Pubitemid 44116705)
6. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372-7. (Pubitemid 36842552)
7. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005;175(11):7746-54. (Pubitemid 41713475)
8. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100(8):4712-7. (Pubitemid 36457795)
9. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, editors. Cancer incidence and survival among children and adolescents. Bethesda: National Cancer Institute; 1999. p. 99-110. NIH Pub. No. 99-4649.
10. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75(1 Suppl):203-10.
11. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531-43.
12. Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30(12):1051-5.
13. Wang W, Wang J, Song H, Liu J, Song B, Cao X. Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 2011;15(7-8):503-6.
14. He J, Wang J, Wang D, Dai S, Yv T, Chen P, et al. Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population. Endocrine. 2014;45(2):325-30.
15. Yu F, Miao J. Significant association between cytotoxic T lymphocyte antigen 4+49G>A polymorphism and risk of malignant bone tumors. Tumour Biol. 2013;34(6):3371-5.
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-48.
17. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58. (Pubitemid 34746062)
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. (Pubitemid 17189972)
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34. (Pubitemid 27387172)
22. Yang S, Wang C, Zhou Y, Sun G, Zhu D, Gao S. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to Ewing's sarcoma. Genet Test Mol Biomarkers. 2012;16(10):1236-40.
23. Feng D, Yang X, Li S, Liu T, Wu Z, Song Y, et al. Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma. Genet Test Mol Biomarkers. 2013;17(6):458-63.
24. Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet. 2006;165(2):114-20. (Pubitemid 43343504)
25. Jaiswal PK, Singh V, Mittal RD. Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in North Indian population. Mol Biol Rep. 2014;41(2):799-807.
26. Qiu H, Tang W, Yin P, Cheng F, Wang L. Cytotoxic T-lymphocyte-associated antigen-4 polymorphisms and susceptibility to cervical cancer: a meta-analysis. Mol Med Rep. 2013;8(6):1785-94.
27. Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991;147(3):1037-44.
28. Seder RA, Germain RN, Linsley PS, Paul WE. CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production. J Exp Med. 1994;179(1):299-304. (Pubitemid 24012995)
29. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. J Immunol. 2011;187(7):3466-74.
30. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol. 1999;162(10):5813-20. (Pubitemid 29314933)
31. Bai XF, Liu J, May KF Jr, Guo Y, Zheng P, Liu Y. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo. Blood. 2002;99(8):2880-9. (Pubitemid 34525377)
32. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-52. (Pubitemid 32368035)